AdipoLABs Expands Korea-China Medical Cooperation… Accelerating Entry into Global Market

Participation in the integrated booth of the 'China Chengdu International Nursing Care Service Industry Expo' and successful hosting of the international conference

[Medical Newspaper/Daily News=Reporter Oh In-gyu] AdipoLABs, widely known as the manufacturer of the high-frequency hyperthermia cancer treatment device, REMISSION 1℃, is drawing attention by establishing a foundation for expanding medical cooperation between Korea and China and entering the global market. AdipoLABs (CEO Han Sung-ho) announced on the 13th that the company participated in the ‘8th China Chengdu International Nursing Service Industry Expo’ that was recently held successfully in Chengdu, Sichuan Province, China.

AdipoLABs CEO Han Sung-ho (6th from the left in the photo) attending the China Chengdu International Nursing Care Service Industry Expo

At this exhibition, AdipoLABs set up an integrated booth under the name of ‘KOREA MEDICAL CENTER’ and explained cancer treatment cases and treatment principles through medical tourism related to treatment and hyperthermia and immunotherapy using the company’s high-frequency hyperthermia cancer treatment device, REMISSION 1℃.

REMISSION 1℃ is a medical device that raises our body temperature to over 40℃, improves blood circulation and immunity, and is used for cancer treatment and pain relief. In addition, REMISSION 1℃ has sponsored the IVRA (International Virus Research Alliance) every year, and has focused the attention of medical professionals at home and abroad by verifying its academic effectiveness in cancer treatment as well as pain management in many countries internationally. Through the participating Korean hospitals and companies, consultations on health foods, colon cancer diagnostic kits, and women's diseases were provided, bestowing an opportunity to publicize the excellence of Korean medical devices and the medical industry.

Meanwhile, AdipoLABs also held an ‘International Conference on Treatment of Korean and Chinese Cancer Patients’ during the event. The speakers at the international conference that day included Professor Jang Hong-seok of Seoul St. Mary’s Hospital, Director Yoo Seung-mo of Yesan Myongji Hospital, Director Lee Chan-yong of Seoul Oncare Hospital, and Director Ahn Seong-hwan of Yonsei Line Hospital.

CEO Han Sung-ho explaining the operating principle of the high-frequency hyperthermia cancer treatment device, REMISSION 1℃

Also in attendance were Vice Chairman Wang Qingquan of the Sichuan Red Cross Society of China, Vice Chairman Mao Zenglin of Deokindang Holdings, Chairman Huang Zaijun of the Party Committee of Chengdu Emperor Military Hospital and Huang Rheumatism Group, President Shu Fengcheng of Dujiang Yan Fengcheng Pain Hospital, and DR. Kenny Yong yean-sirn of Malaysia, who gave in-depth academic presentations on the latest cancer treatment technology and cooperation plans. The last speaker, CEO Han Sung-ho, who is the co-CEO of AdipoLABs and IVRA, presented a roadmap for medical tourism, a common interest between Korea and China, and proposed cooperation plans to promote friendly medical relations between the two countries.

The conference ended with a promotional video asking for tremendous participation in the '8th 2025 IVRA International Medical Conference' scheduled to be held at the Seoul St. Mary's Hospital Seongui Hall on June 22.

CEO Han Sung-ho said, "We expect this exhibition and conference to serve as a stepping stone for expanding medical cooperation between Korea and China and entering the global market in the future," and expressed his ambition by saying, "We will do our best to spread and promote advanced domestic medical technologies for cancer treatment, starting with China, and aggressively head for the Chinese market with promotion."

Source: http://www.bosa.co.kr/news/articleView.html?idxno=2243925